查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933338

外分泌胰臟功能不全治療市場規模、佔有率、成長、全球產業分析：依類型、應用、區域洞察、預測（2026-2034 年）

Exocrine Pancreatic Insufficiency Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 128 Pages | 商品交期: 請詢問到貨日

價格

外分泌胰臟功能不全 (EPI) 治療市場成長因子

由於胰臟疾病盛行率的上升以及人們對消化系統健康意識的增強，全球外分泌胰臟功能不全 (EPI) 治療市場正經歷穩定成長。外分泌胰臟功能不全是一種以胰臟外分泌酶缺乏為特徵的疾病，會導致消化不良和營養吸收不良。由於症狀通常不明顯且容易被忽視，因此診斷通常需要進行專門的檢查，包括血液檢查、糞便檢查和胰腺功能評估。 2025年，該市場價值為24.3億美元，預計2026年將成長至25.5億美元，到2034年將達到35.1億美元。這意味著2026年至2034年的複合年增長率（CAGR）為4.06%。北美在2025年以3.85%的市佔率領先，這得益於較高的認知度、先進療法的快速應用以及強大的研發基礎設施。

市場驅動因素與趨勢

認知度提升與治療創新

外分泌胰臟炎（EPI）治療市場的成長是由人們對該疾病及其全身影響的認知度提高所驅動的。急性胰臟炎、囊性纖維化和胰臟腫瘤是導致EPI盛行率顯著增加的重要因素。例如，2019 年 10 月，AzurRx BioPharma 開始為患者使用 MS1819-SD，這是一種用於治療外分泌胰腺功能不全 (EPI) 的創新療法。人們對 EPI 的認識不斷提高，推動了胰酶替代療法 (PERT) 等療法的研發和應用，而 PERT 一直是傳統上最有效的治療方法。

相關疾病的成長趨勢

包括自體免疫性胰臟炎和施瓦赫曼-戴蒙德症候群在內的胃腸道和胰臟疾病的盛行率直接影響 EPI 的發生率。這推動了治療研發領域的持續創新，提高了療效和安全性，並促進了全球市場的擴張。

技術與臨床進展

診斷工具和治療方案的進步，以及研發投入的增加，正在推動治療方案的改進。由於其高效性、有效性和已確立的臨床療效，胰酶替代療法 (PERT) 佔市場主導地位，預計到 2025 年將創造 21.2 億美元的收入。

市場區隔

依療法

  • 胰酵素替代療法 (PERT)：由於其臨床療效和廣泛應用，PERT 佔市場主導地位，並以最高的複合年增長率 (CAGR) 成長。
  • 營養療法：支持患者管理，但市佔率較小，成長率較低。外分泌性胰臟功能不全 (EPI) 患者的營養不良會導致併發症和死亡率增加，凸顯了該細分市場的重要性。

依分銷管道

  • 醫院藥局：處方通常在臨床診斷後開立，因此預計將保持最大的市場佔有率（2025 年為 67.9%）。
  • 零售藥局和藥局：便利性以及與線上藥局日益緊密的整合將促進二次成長。

區域分析

預計北美市場將在2025年以18.9億美元的規模引領市場，並在2026年增長至19.8億美元，這主要得益於強勁的研發投入、較高的治療普及率以及疾病認知度的提高。光是美國市場預計到2026年就將達到16.9億美元。

亞太地區預計將實現最快成長，這主要得益於可支配收入的增加、先進療法的普及以及公眾意識的提高。主要市場包括日本（2026年9000萬美元）、中國（2026年6000萬美元）和印度（2026年3000萬美元）。

由於低滲透率地區存在發展機遇，預計歐洲市場將維持穩定成長。由於公眾意識的提高和治療途徑的改善，英國（2026年預計為5000萬美元）和德國（2026年預計為7000萬美元）等國家的市場正在擴張。

由於市場滲透率低且醫療基礎設施尚在發展中，預計拉丁美洲以及中東和非洲地區的市場成長速度將放緩。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 與外分泌胰臟功能不全相關的主要疾病的盛行率
  • 研發管線分析
  • 近期產業趨勢，包括併購、合作與收購
  • 監理環境
  • 新產品發布

第五章：全球外分泌胰臟功能不全治療市場分析、洞察與預測 2021-2034

  • 主要發現/摘要
  • 依療法劃分的市場分析、見解和預測
    • 胰酵素替代療法 (PERT)
      • CREON
      • ZenPep
      • 其他
    • 營養療法
  • 依分銷管道劃分的市場分析、洞察與預測
    • 醫院藥房
    • 零售藥局和藥局
    • 其他
  • 依國家/地區劃分的市場分析、洞察與預測
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區

第六章 北美外分泌胰臟功能不全治療市場分析、洞察與預測 2021-2034

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲外分泌胰臟功能不全治療市場分析、洞察與預測，2021-2034

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區

第八章：亞太地區外分泌胰臟功能不全治療市場分析、洞察與預測，2021-2034

  • 依國家/地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 亞太其他地區

第九章：世界其他地區外分泌胰臟功能不全治療市場分析、洞察與預測（2021-2034）

第十章：競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025）
  • 競爭概覽
  • 競爭分析
  • 公司簡介
    • AbbVie Inc.
    • Janssen Pharmaceuticals, Inc.
    • Allergan
    • AzurRx
    • CHIESI Farmaceutici S.p.A.
    • Other Prominent Players
Product Code: FBI100652

Growth Factors of exocrine pancreatic insufficiency (EPI) therapeutics Market

The global exocrine pancreatic insufficiency (EPI) therapeutics market is witnessing steady growth due to the rising prevalence of pancreatic disorders and increasing awareness of gastrointestinal health. Exocrine pancreatic insufficiency is a condition marked by the deficiency of exocrine pancreatic enzymes, resulting in maldigestion and nutrient malabsorption. Diagnosis often involves specialized tests such as blood, stool, and pancreatic function assessments, as symptoms are frequently under-detected. In 2025, the market was valued at USD 2.43 billion, projected to grow to USD 2.55 billion in 2026, and expected to reach USD 3.51 billion by 2034, reflecting a CAGR of 4.06% from 2026 to 2034. North America dominated the market in 2025 with a 3.85% share, supported by high awareness, rapid adoption of advanced therapies, and robust R&D infrastructure.

Market Drivers and Trends

Rising Awareness and Therapeutic Innovations

The growth of the EPI therapeutics market is fueled by increased awareness of the disorder and its impact on overall health. Acute pancreatitis, cystic fibrosis, and pancreatic tumors are major contributors to EPI prevalence. For instance, in October 2019, AzurRx BioPharma dosed patients with MS1819-SD, an innovative therapeutic for EPI. The rising recognition of EPI has propelled the development and adoption of therapies such as Pancreatic Enzyme Replacement Therapy (PERT), which remains the conventional and most effective treatment.

Increasing Prevalence of Associated Disorders

The prevalence of gastrointestinal and pancreatic disorders, including autoimmune pancreatitis and Shwachman-Diamond syndrome, directly influences EPI incidence. This has led to continued R&D innovation in therapeutics, enhancing efficacy and safety profiles, which drives market expansion globally.

Technological and Clinical Advancements

Advancements in diagnostic tools and treatment regimens, coupled with rising R&D investments, have facilitated improved therapeutic options. PERT, projected to generate USD 2.12 billion in revenue by 2025, dominates the market due to its efficiency, potency, and established clinical outcomes.

Market Segmentation

By Therapy

  • Pancreatic Enzyme Replacement Therapy (PERT): Dominates the market, growing at the highest CAGR due to its clinical effectiveness and broad adoption.
  • Nutritional Therapy: Supports patient management but holds a smaller share and lower growth rate. Poor nutrition in EPI patients can lead to increased complications and mortality, highlighting the importance of this segment.

By Distribution Channel

  • Hospital Pharmacies: Expected to hold the largest share (67.9% in 2025) as prescriptions are typically issued after clinical diagnosis.
  • Retail Pharmacies & Drug Stores: Offer convenience and increasing online pharmacy integration, supporting secondary growth.

Regional Analysis

North America dominated the market with USD 1.89 billion in 2025, rising to USD 1.98 billion in 2026, driven by strong R&D, high treatment adoption, and increasing disease awareness. The U.S. market alone is projected to reach USD 1.69 billion by 2026.

Asia Pacific is poised for the fastest growth due to increasing disposable incomes, adoption of advanced therapeutics, and better awareness. Key markets include Japan (USD 0.09 billion in 2026), China (USD 0.06 billion in 2026), and India (USD 0.03 billion in 2026).

Europe is growing steadily with opportunities in under-penetrated regions. Countries such as the U.K. (USD 0.05 billion in 2026) and Germany (USD 0.07 billion in 2026) are expanding due to rising awareness and improved therapeutic access.

Latin America and Middle East & Africa are expected to experience moderate growth due to under-penetration and emerging healthcare infrastructure.

Competitive Landscape

The market is concentrated with major players such as AbbVie Inc., Janssen Pharmaceuticals, and Allergan, leveraging broad product portfolios and global presence. Smaller and emerging players, including AzurRx and CHIESI Farmaceutici S.p.A., contribute through innovation and new therapeutic pipelines. AbbVie's 2024 gastroenterology portfolio update at the ECCO Congress highlights ongoing R&D commitment to EPI and related disorders.

Conclusion

The global exocrine pancreatic insufficiency therapeutics market is set to expand from USD 2.43 billion in 2025 to USD 3.51 billion by 2034, at a CAGR of 4.06%. Market growth is primarily driven by increasing prevalence of associated disorders, rising awareness, innovations in therapeutics such as PERT, and robust R&D investments. North America remains the dominant region, while Asia Pacific offers the fastest growth potential due to rising healthcare adoption and disposable incomes. Despite challenges like under-penetration in certain regions and ongoing regulatory requirements, the EPI therapeutics market is positioned for sustained growth over the forecast period.

Segmentation By Therapy

  • Pancreatic Enzyme Replacement Therapy (PERT)
    • Creon
    • Zenpep
    • Others
  • Nutritional Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Major Disorders Associated With Exocrine Pancreatic Insufficiency
  • 4.2. Pipeline Analysis
  • 4.3. Recent Industry Developments Such as Mergers, Partnerships & Acquisitions
  • 4.4. Regulatory Scenario
  • 4.5. New Product Launches

5. Global Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Therapy
    • 5.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 5.2.1.1. Creon
      • 5.2.1.2. Zenpep
      • 5.2.1.3. Others
    • 5.2.2. Nutritional Therapy
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies & Drug Stores
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Country
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Therapy
    • 6.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 6.2.1.1. Creon
      • 6.2.1.2. Zenpep
      • 6.2.1.3. Others
    • 6.2.2. Nutritional Therapy
  • 6.3. Market Analysis - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies & Drug Stores
    • 6.3.3. Others
  • 6.4. Market Analysis - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Therapy
    • 7.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 7.2.1.1. Creon
      • 7.2.1.2. Zenpep
      • 7.2.1.3. Others
    • 7.2.2. Nutritional Therapy
  • 7.3. Market Analysis - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies & Drug Stores
    • 7.3.3. Others
  • 7.4. Market Analysis - By Country
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Therapy
    • 8.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 8.2.1.1. Creon
      • 8.2.1.2. Zenpep
      • 8.2.1.3. Others
    • 8.2.2. Nutritional Therapy
  • 8.3. Market Analysis - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies & Drug Stores
    • 8.3.3. Others
  • 8.4. Market Analysis - By Country
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Rest of Asia Pacific

9. Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Therapy
    • 9.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 9.2.1.1. Creon
      • 9.2.1.2. Zenpep
      • 9.2.1.3. Others
    • 9.2.2. Nutritional Therapy
  • 9.3. Market Analysis - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies & Drug Stores
    • 9.3.3. Others
  • 9.4. Market Analysis - By Country

10. Competitive Analysis

  • 10.1. Key Industry Developments
  • 10.2. Global Market Share Analysis (2025)
  • 10.3. Competition Dashboard
  • 10.4. Comparative Analysis - Major Players
  • 10.5. Company Profiles
    • 10.5.1. AbbVie Inc.
      • 10.5.1.1. Overview,
      • 10.5.1.2. Products & services,
      • 10.5.1.3. SWOT analysis,
      • 10.5.1.4. Recent developments,
      • 10.5.1.5. strategies,
      • 10.5.1.6. financials (based on availability)
    • 10.5.2. Janssen Pharmaceuticals, Inc.
      • 10.5.2.1. Overview,
      • 10.5.2.2. Products & services,
      • 10.5.2.3. SWOT analysis,
      • 10.5.2.4. Recent developments,
      • 10.5.2.5. strategies,
      • 10.5.2.6. financials (based on availability)
    • 10.5.3. Allergan
      • 10.5.3.1. Overview,
      • 10.5.3.2. Products & services,
      • 10.5.3.3. SWOT analysis,
      • 10.5.3.4. Recent developments,
      • 10.5.3.5. strategies,
      • 10.5.3.6. financials (based on availability)
    • 10.5.4. AzurRx
      • 10.5.4.1. Overview,
      • 10.5.4.2. Products & services,
      • 10.5.4.3. SWOT analysis,
      • 10.5.4.4. Recent developments,
      • 10.5.4.5. strategies,
      • 10.5.4.6. financials (based on availability)
    • 10.5.5. CHIESI Farmaceutici S.p.A.
      • 10.5.5.1. Overview,
      • 10.5.5.2. Products & services,
      • 10.5.5.3. SWOT analysis,
      • 10.5.5.4. Recent developments,
      • 10.5.5.5. strategies,
      • 10.5.5.6. financials (based on availability)
    • 10.5.6. Other Prominent Players
      • 10.5.6.1. Overview,
      • 10.5.6.2. Products & services,
      • 10.5.6.3. SWOT analysis,
      • 10.5.6.4. Recent developments,
      • 10.5.6.5. strategies,
      • 10.5.6.6. financials (based on availability)

List of Tables

  • Table 1: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 2: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 3: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 6: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 7: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 10: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 11: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 15: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 18: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 19: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Figure 4: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Nutritional Therapy, 2021-2034
  • Figure 5: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 7: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Retail Pharmacies & Drug Stores, 2021-2034
  • Figure 8: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 9: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 10: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 11: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 12: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 13: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 14: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 15: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country, 2025
  • Figure 16: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 17: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 18: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 25: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 26: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 27: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 28: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 29: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 30: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 31: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 32: Global Exocrine Pancreatic Insufficiency Therapeutics Market Share (%), By Company, 2025